1 **Peripheral blood leukocyte signatures as biomarkers in relapsed ovarian cancer** 2 **patients receiving combined anti-CD73/anti-PD-L1 immunotherapy in Arm A of the** 3 **NSGO-OV-UMB1/ENGOT-OV30 trial**

4

5 Luka Tandaric^{1,2}, Annika Auranen^{3,4}, Katrin Kleinmanns¹, René DePont Christensen⁵, Liv 6 Cecilie Vestrheim Thomsen^{1,2,6}, Cara Ellen Wogsland^{1,7}, Emmet McCormack^{1,8,9}, 7 Johanna Mäenpää^{3,4,10}, Kristine Madsen⁵, Karen Stampe Petersson⁵, Mansoor Raza 8 Mirza^{5,11}, Line Biørge^{*,1,2}

9

10 ¹ Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of

- 11 Bergen, Bergen, Norway
- 12 ² Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen,
- 13 Norway
- ³ Department of Obstetrics and Gynecology and Tays Cancer Centre, Tampere University
- 15 Hospital, Tampere, Finland
- ⁴ Nordic Society of Gynaecological Oncology Clinical Trial Unit (NSGO-CTU), Tampere,
- 17 Finland
- 18 ⁵Nordic Society of Gynaecological Oncology Clinical Trial Unit (NSGO-CTU),
- 19 Copenhagen, Denmark
- 20 ⁶ Department of Health Registry Research and Development, Norwegian Institute of
- 21 Public Health, Oslo, Norway
- 22 ⁷ Kinn Therapeutics AS, Bergen, Norway

- ⁸ Centre for Pharmacy, Department of Clinical Science, University of Bergen, Bergen,
- 24 Norway
- ⁹ Department of Internal Medicine, Hematology Section, Haukeland University Hospital,
- 26 Bergen, Norway
- 27 ¹⁰ Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
- ¹¹ Department of Oncology, Rigshospitalet, Copenhagen University Hospital,
- 29 Copenhagen, Denmark
- 30 *Corresponding author
- 31
- 32
- 33
-
-
- 34
- 35
-
- 36
- 37
-
- 38
- 39
- 40
- 41
-
- 42

43 **ABSTRACT**

44 **Background:** Clinical trials of immune checkpoint inhibitors in epithelial ovarian cancer 45 (EOC) have not shown clear survival benefit, likely due to the complex 46 immunosuppressive mechanisms of the EOC tumor microenvironment. Still, certain 47 patients experience long-term treatment benefit. However, we lack reliable biomarkers 48 for distinguishing dominant immunosuppressive mechanisms and for identifying patients 49 with EOC who are responsive to immunotherapy. The present high-dimensional single-50 cell study analyzed patients with relapsed EOC enrolled in arm A of the NSGO-OV-51 UMB1/ENGOT-OV30 trial, wherein the patients underwent combination oleclumab (anti-52 CD73) and durvalumab (anti-PD-L1) immunotherapy. The objective of the study was the 53 identification of blood-based immunophenotypic signatures conducive to the 54 development of improved strategies for patient selection, response monitoring, and 55 personalized targeting of immunosuppressive mechanisms.

56 **Methods:** A 40-marker suspension mass cytometry panel was utilized for 57 comprehensive phenotypic and functional characterization of longitudinally sampled 58 peripheral blood leukocytes from patients. Artificial neural network-based unsupervised 59 clustering and manual metacluster curation were used to identify leukocyte subsets for 60 differential discovery and correlation analyses.

61 **Results:** At baseline, short-term and long-term survivors differed with regard to the 62 relative abundances of total peripheral blood mononuclear cells (PBMCs). We observed 63 a significant increase in CD14⁺CD16⁻ myeloid cells during treatment, initially driven by 64 classical monocyte proliferation and subsequently driven by the expansion of monocytic 65 myeloid-derived suppressor cells (M-MDSCs). This M-MDSC expansion occurred only in

66 patients with shorter progression-free survival, who also showed a continuous decrease 67 in central memory T-cell abundances after baseline. Throughout treatment, we observed 68 upregulation of PD-L1 expression on most T-cell subsets in all patients. Higher 69 expression of CD73 and IDO1 on select leukocyte subsets at baseline was significantly 70 positively correlated with longer progression-free survival.

71 **Conclusions:** Our study delineates the phenotypic and functional alterations in 72 peripheral blood leukocytes occurring during combination oleclumab/durvalumab 73 immunotherapy in patients with relapsed EOC. We propose a set of biomarkers with 74 potential for treatment personalization and response monitoring: relative abundances of 75 PBMCs at baseline, relative abundances of M-MDSCs and central memory T cells 76 during treatment; PD-L1 expression levels over time; and baseline expression of CD73 77 and IDO1 on specific leukocyte subsets. However, validation of these biomarkers 78 through larger-scale studies is required.

79

80 **KEY MESSAGES**

81 **WHAT IS ALREADY KNOWN ON THIS TOPIC**

82 Despite promising preclinical results and moderate efficacy in lung cancer, combination 83 anti-CD73/anti-PD-L1 immunotherapy in relapsed epithelial ovarian cancer (EOC) has 84 shown only modest response rates, consistent with other EOC immunotherapy trials. 85 Durable clinical benefit remains rare, and there are currently no biomarkers available for 86 the effective selection of EOC patients for personalized immunotherapy and for the 87 characterization of sustained responses.

88 **WHAT THIS STUDY ADDS**

89 This study demonstrates that, at baseline of combination anti-CD73/anti-PD-L1 90 treatment, EOC patients with higher relative abundances of peripheral blood 91 mononuclear cells (PBMCs) and elevated expression of CD73 and IDO1 on certain 92 PBMC subsets may experience greater overall survival and progression-free survival 93 benefit, respectively. Additionally, patients with faster disease progression exhibited a 94 shift in CD14⁺CD16⁻ myeloid cells towards a more immunosuppressive phenotype and 95 had lower abundances of central memory T cells over time compared to patients with 96 slower progression, while PD-L1 expression increased significantly over time on T cells 97 of all patients, regardless of the rate of disease progression.

98

99 **HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY**

100 While further clinical validation is required, we propose blood-based biomarkers for 101 predicting and monitoring responses to immunotherapy in EOC, aiming to guide future 102 research on immunotherapy resistance mechanisms and treatment personalization, with 103 a focus on specific peripheral leukocyte subsets.

104

105 **KEYWORDS**

106 Humans; Epithelial ovarian cancer; Immunotherapy; Immune checkpoint inhibitor; 107 durvalumab; oleclumab; Mass Cytometry; Myeloid-derived suppressor cells; Leukocytes, 108 Mononuclear; Biomarkers

109 **INTRODUCTION**

110 Epithelial ovarian cancer (EOC) is predominantly diagnosed at an advanced stage. For 111 the past few decades, surgical cytoreduction followed by carboplatin-paclitaxel 112 chemotherapy has been the default approach to treating EOC [1]. Recently, the clinical 113 implementation of poly(ADP-ribose) polymerase inhibitors (PARPi's) and the anti-114 angiogenesis agent bevacizumab as maintenance therapy has significantly improved 115 survival [2]. However, despite most patients initially responding to primary treatment, 116 70%-80% of the responders eventually experience relapse [3]. Although multiple 117 therapeutics are used to treat recurrent disease, the treatment intent shifts from curative 118 to palliative. Drug resistance and the dearth of effective post-relapse treatment options 119 have resulted in the long-term survival rates remaining low [4] and highlighted the need 120 for novel treatment modalities.

121

122 Immunotherapy, particularly the clinical implementation of immune checkpoint inhibitors 123 (ICIs), has improved the outcomes of several cancers by disrupting tumor immune 124 evasion mechanisms, mainly the induction of T-cell exhaustion [5]. Seminal studies by 125 Zhang et al. [6] and Curiel et al. [7], correlating treatment response and survival with the 126 presence, position, and phenotypes of tumor-infiltrating lymphocytes in EOC, have 127 indicated rationale for applying immunotherapy in EOC as well. Although numerous trials 128 on immunotherapeutic regimens in EOC have been conducted, including studies 129 incorporating patient pre-selection strategies based on predictive biomarkers, such as 130 PD-L1 [8], none have shown sufficient efficacy to be considered clinically viable [9]. 131 Immunotherapy has failed to achieve potency in EOC on account of multiple

132 immunoinhibitory mechanisms simultaneously active in its tumor microenvironment 133 (TME). This facilitates a high degree of immunosuppression, unsurmountable by 134 immunotherapeutics delivered either as a monotherapy or in combination with 135 chemotherapeutics [10]. In preclinical studies on EOC, combination immunotherapy 136 regimens have resulted in notable increases in antitumor efficacy over single-agent 137 immunotherapeutics, predominantly by inhibition of PD-1/PD-L1 interaction alongside 138 simultaneous activation of an immunostimulatory receptor on T cells [11].

139

140 Building off of promising preclinical results of combination immunotherapies in murine 141 models of solid cancers, which had shown significant synergistic effects in terms of 142 tumor reduction and survival improvement, as well as elevated abundance and anti-143 tumor activity of CDB^+ T cells, compared to the corresponding monotherapies [12-14], 144 the non-randomized phase II trial NSGO-OV-UMB1/ENGOT-OV30 was designed as a 145 three-arm umbrella trial for testing the clinical efficacy of several novel combinations of 146 immunotherapeutics in patients with relapsed EOC [15]. The treatment in arm A 147 comprised oleclumab and durvalumab - human monoclonal IgG1 antibodies that target 148 and inhibit CD73 and PD-L1, respectively. CD73, an adenosine-generating extracellular 149 enzyme present on most normal tissues [16], is overexpressed in most cancers [17] and 150 associated with poor prognosis in EOC [18]. Binding of adenosine to A2A receptors on 151 antigen-activated T cells results in activation blockage and exhaustion [19]. Accordingly, 152 inhibition of the CD73/A2A receptor axis is considered an effective means of re-153 invigorating anti-tumor immunity [20]. Furthermore, simultaneous inhibition of CD73 and 154 the PD-1/PD-L1 interaction in preclinical *in vitro* and *in vivo* human cell line models was 155 shown to have a synergistic anti-tumor effect compared to the individual inhibition of

156 either [21]. Based on these results, the oleclumab/durvalumab combination was 157 approved for testing in a phase II clinical trial setting [15]. While it demonstrated only 158 marginal clinical efficacy in a relapsed EOC cohort, a number of patients exhibited 159 prolonged survival.

160

161 This translational study presents the results of the high-dimensional single-cell 162 suspension cytometry by time-of-flight (CyTOF) analysis of blood samples collected from 163 trial cohort A prior to treatment and at regular intervals during treatment. The aim was 164 the elucidation of clinically actionable phenotypic signatures of the response of relapsed 165 EOC to oleclumab/durvalumab immunotherapy. We identified potential leukocyte-based 166 predictive, prognostic, and response biomarkers for the purposes of improved patient 167 selection, preemptive detection of cancer progression, and portrayal of *in vivo* drug 168 activity, respectively.

169

170 **METHODS**

171 **Patient cohort and samples**

172 In the international NSGO-OV-UMB1/ENGOT-OV-30 umbrella trial, 25 immunotherapy-173 naïve patients with relapsed EOC who had CD73-positive archival tumor samples were 174 included in arm A and intravenously administered 3000 mg oleclumab and 1500 mg 175 durvalumab every two and four weeks, respectively (figure 1A). The primary endpoint 176 was response evaluation (disease control rate) at the 16-week timepoint. Peripheral 177 blood samples for single-cell suspension CyTOF were collected in 10 mL EDTA 178 Vacutainer tubes (Becton Dickinson, REF 367525) at baseline (pre-treatment), at 179 minimum every two 28-day cycles, and at end of trial or at disease progression. Within

180 one hour of collection, samples were processed using BD Phosflow Lyse/Fix buffer 181 (Becton Dickinson, REF 558049) and frozen at -80°C (figure 1B,C) (protocol described 182 in the online supplemental appendix). Samples were stored in the biobank of Haukeland 183 University Hospital, Bergen, Norway.

184

185 **Mass cytometry panel development**

186 A 40-marker antibody panel (online supplemental table S1) encompassing the entire 187 human peripheral blood leukocyte repertoire was designed and developed in-house for 188 in-depth single-cell analysis of the leukocyte samples. As the aim of 189 oleclumab/durvalumab immunotherapy was the reinvigoration of T cells from an 190 exhausted state, a central objective of the panel was ascertainment of information about 191 T-cell states before and during treatment. Given that myeloid cells in the peripheral 192 blood have been observed to significantly influence the outcome of immunotherapy of 193 solid cancers [22], as well as have a crucial influence on treatment outcome upon 194 settlement into the TME of EOC [23], another objective of the panel was the 195 characterization of the myeloid cells in the samples.

196 For antibody clones not commercially available in a pre-metal-conjugated format, 100 µg 197 of purified, carrier-protein-free antibody was conjugated in-house to cadmium- or 198 lanthanide-loaded polymers using Maxpar MCP9 or X8 antibody labeling kits, 199 respectively, according to the manufacturer's protocol (Standard BioTools).

200 Antibodies were titrated on leukocytes from whole blood collected from healthy female 201 donors and processed using the Lyse/Fix buffer. Titration of lineage and cell state

202 markers was performed on unstimulated leukocytes, and peripheral blood mononuclear 203 cells (PBMCs) stimulated *in vitro* by interleukin-2 (IL-2) (Sigma, Cat.No. I2644) and 204 phytohemagglutinin-P (PHA-P) (Sigma, Cat.No. 61764), respectively, according to the 205 protocol in the online supplemental appendix. To ensure consistency, identical sample 206 processing and staining protocols were maintained for the titration samples and clinical 207 samples. The optimal concentration of Cell-ID Intercalator-Ir (Standard BioTools, Cat.No. 208 201192B) for the identification of nucleated cells was determined to be 250 nM by 209 titration. The panel was validated for use on the CyTOF XT mass cytometer (Standard 210 BioTools).

211

212 **Sample staining and data acquisition**

213 To facilitate uniform staining, batches containing up to 20 samples were designed, 214 wherein a unique palladium-based tag was assigned to each sample. For batch effect 215 correction, each barcoded batch contained two different anchor samples consisting of 216 Lyse/Fix-treated healthy donor leukocytes, one of which had an admixture of PHA-P/IL-217 2-treated healthy donor PBMCs to enable batch correction of activation/exhaustion 218 markers. Frozen fixed leukocyte samples were thawed and treated with 0.25 mg/mL 219 DNAse I (Sigma, Cat.No. DN25) dissolved in Dulbecco's phosphate-buffered saline 220 containing Ca^{2+} and Mg²⁺ (Sigma, Cat.No. D8662) (henceforth referred to as "DNAse"). 221 Cells were counted, and a maximum of 3.5×10^6 cells from each sample were tagged 222 using a palladium-based barcoding method according to the manufacturer's protocol 223 (Standard BioTools, Cat.No. 201060). Barcoding reagents were washed away, and all 224 cells within a batch were pooled, counted, and frozen at -80°C.

225 To maintain consistency in the composition of staining antibody mixes across sample 226 batches, two mixes of antibodies, targeting either surface or intracellular markers, were 227 pre-made in quantities large enough to stain the full set of samples, aliquoted, and 228 stored at -80°C. Comparative testing of frozen versus freshly-made antibody mixes on 229 Lyse/Fix-treated healthy donor leukocytes demonstrated that freezing did not affect the 230 effectiveness or specificity of the panel antibodies.

231 For staining, barcoded sample mixes were thawed and counted. Cells were then 232 incubated in MaxPar Cell Staining Buffer (CSB) (Standard BioTools, Cat.No. 201068) 233 containing human FcR Blocking Reagent (Miltenyi Biotec, Cat.No. 130-059-901), and 234 heparin (Ratiopharm, Reg.No. 5394.00.00) to prevent non-specific antibody binding. 235 Aliquots of the antibody mix for staining cell surface proteins were thawed and added to 236 the cells at 3×10^6 cells per 100 µL of staining volume. After incubating for 45 minutes at 237 room temperature (RT), superfluous antibody was washed away with MaxPar CSB, then 238 with MaxPar phosphate-buffered saline (PBS) (Standard BioTools, Cat.No. 201058), 239 after which cells were permeabilized by a 10-minute incubation in pure methanol 240 (Sigma, Cat.No. 32213) at -20°C. The methanol was washed away with MaxPar PBS, 241 followed by MaxPar CSB. Aliquots of the antibody mix for targeting intracellular proteins 242 were thawed and applied to the permeabilized cells for 30 minutes at RT, at a 243 concentration of 3×10^6 cells per 100 μ L of staining volume. For DNA staining, washed 244 cells were incubated with iridium intercalator diluted in MaxPar PBS containing 4% V/V 245 formaldehyde for 20 min at RT. The cells were washed, resuspended in a 10% V/V 246 solution of dimethyl-sulfoxide (Sigma, Cat.No. W387520) in fetal bovine serum (Sigma, 247 Cat.No. F7524) and frozen at -80°C.

248 For data acquisition, fully stained cells were thawed, washed using MaxPar CSB, and 249 incubated in DNAse. Cells were then washed and pelleted in MaxPar Cell Acquisition 250 Solution (Standard BioTools, Cat.No 201240), kept on ice until data acquisition, and 251 acquired in MaxPar Cell Acquisition Solution Plus (Standard BioTools, Cat.No. 201244). 252 High-dimensional data from three barcoded batches was acquired on a CyTOF XT mass 253 cytometer at ~400 events per second, with EQ Six-Element Calibration Beads (Standard 254 BioTools, Cat.No. 201245) present in the suspension at a 1:10 dilution (detailed 255 barcoding and staining methodologies provided in the online supplemental appendix).

256

257 **Data pre-processing**

258 Bead-based longitudinal signal intensity normalization was done automatically by the 259 CyTOF XT software upon data acquisition. Events were de-barcoded using the MATLAB 260 Compiler Runtime (R2013a(8.1)) implementation of The Single Cell Debarcoder by 261 Zunder et al. [24]. De-barcoded events were uploaded to Cytobank (Beckman Coulter 262 Inc.), where irregular events were removed by manual gating (online supplemental figure 263 S1). The resulting single-cell events were batch corrected with the R-based GUI 264 implementation of CytofBatchAdjust by Schuyler et al. (v0.0.0.9001) [25], using the 265 composite anchor sample of each batch. Batch correction effectiveness was assessed 266 by analyzing the corrected data of the alternate anchor sample.

267

268 **Clustering and differential analyses**

269 Unsupervised clustering, dimensionality reduction, manually curated metaclustering, and 270 differential analyses were performed using the "flowSOM" [26], "umap" [27], 271 "CATALYST" [28], and "diffcyt" [29] R packages, respectively.

272 Total leukocyte data from all patient samples was first clustered into a 64-cluster (8×8) 273 self-organizing map (SOM) and manually metaclustered into granulocyte, PBMC, and 274 debris subsets based on the expression of 13 markers (figure 2A). The assignment of 275 cell identity was rigorously quality checked using biaxial plots, heatmaps, UMAPs, and 276 hierarchical clustering of clusters. The PBMC subset was further sub-clustered into a 277 256-cluster (16×16) SOM and manually grouped into 24 subsets corresponding to 278 widely established PBMC types using 22 markers (figure 2B). Subset assignment was 279 validated in the same manner as that for total leukocytes.

280

281 **Statistical analyses**

282 Differential subset abundance and cell state marker expression between clinical sample 283 groups, stratified by length of survival, duration of progression-free survival (PFS), or 284 sampling timepoint, were analyzed using the edgeR and limma functions of the diffcyt R 285 package, respectively. Multiple hypothesis testing correction was conducted using the 286 Benjamini-Hochberg method, giving adjusted p-values (p_{adi}) .

287 To identify potential predictive biomarkers among baseline leukocyte characteristics, the 288 relationships between PFS duration, and either relative cell subset abundances or state 289 marker expression medians for each cell subset were analyzed using GraphPad Prism 290 (v10.2.0, GraphPad Software). Given that patients in the short-term survivor group had 291 died prior to the first tumor evaluation timepoint, this analysis was restricted to the seven 292 patients in the long-term survivor group. According to the results of Shapiro-Wilk 293 normality testing (alpha=0.05), either a Pearson or Spearman correlation test was 294 performed for each marker-subset combination (dataset) alongside simple linear 295 regression to assess the relationship between PFS duration and relative abundances or 296 expression medians. The p-values in the correlation analyses were not corrected for 297 multiple hypothesis testing due to the small size of datasets $(n=7)$ and the discovery-298 driven nature of this study. To maintain robustness, we considered significant 299 correlations with an absolute correlation coefficient of at least 0.5 and an R-squared 300 value of at least 0.75 as meaningful.

301

302 **RESULTS**

303 **Study cohort demographics**

304 In this retrospective translational study, we analyzed total leukocytes longitudinally 305 sampled from patients with relapsed EOC undergoing combination 306 oleclumab/durvalumab immunotherapy (figure 1A) with the aim of identifying predictive, 307 prognostic, and response biomarkers for the administered treatment. Out of the 25- 308 patient trial cohort, 16 patients were not eligible for this study due to samples either 309 missing or being of inadequate quality (figure 1B). Therefore, the data in this study 310 stems from 36 leukocyte samples of nine patients (figure 1C). Nonetheless, our study 311 cohort is highly representative of the clinical trial cohort [15], as the patient age range 312 and distributions of FIGO stage, ECOG status, and clinical response are similar (table

- 313 1). In contrast to the patients in the clinical trial, the majority of the patients included in
- 314 this study had undergone more extensive treatment prior to inclusion.
-

332 **Table 1** Characteristics of the included patients.

333 *One cycle corresponds to four weeks of treatment.

334 ** Patients passed away prior to the first post-baseline tumor evaluation.

335 FIGO - International Federation of Gynecology and Obstetrics

336 ECOG PS - Eastern Cooperative Oncology Group performance status

338 **CyTOF analysis enabled in-depth characterization of patients' leukocyte profiles**

339 We utilized single-cell suspension CyTOF for high-dimensional phenotypic profiling of 340 patient leukocytes. Approximately 21 million total events were acquired from the 36 341 leukocyte samples. After quality controls, single-cell data of about 19 million leukocytes 342 remained for further analysis. After batch correction, unsupervised clustering using 343 FlowSOM and manual metaclustering of the total leukocytes produced three leukocyte 344 subsets - granulocytes, PBMCs, and debris (figure 2A). To achieve the intended 345 analytical depth, the same clustering and metaclustering procedures were applied in 346 higher resolution to the PBMCs, resulting in the clear delineation of 24 PBMC subsets 347 (figure 2B). The robustness of the PBMC (meta)clustering was confirmed by using the 348 UMAP dimensionality reduction algorithm on an aggregated dataset comprising 10,000 349 PBMCs from each of the 36 samples (figure 2C).

350 All PBMC subtypes, except for the rarest populations (plasmablasts, CD141⁺ myeloid 351 dendritic cells, and CD4⁺CD8⁺ T cells), were detected in all samples (figure 2D, online 352 supplemental table S2). Inspection of the complete dataset revealed that each patient's 353 leukocyte profile remained largely consistent over time, but inter-patient heterogeneity 354 was markedly more pronounced (figure 2D). Nevertheless, certain trends in 355 compositional changes of leukocyte profiles over time were observed, such as the 356 expansion of myeloid cells at the cost of overall T-cell proportions in nearly all patients. 357 To determine the significance of these observations for biomarker discovery, we 358 performed differential analyses of leukocyte composition and cell state marker 359 expression.

360

361 **Long-term survivors exhibit larger abundances of PBMCs at baseline**

362 To identify clinically relevant predictive biomarkers, patients were first stratified into 363 short-term survivors (≤16 weeks, n=2) and long-term survivors (>16 weeks, n=7). We 364 observed that long-term survivors had, on average, significantly higher relative 365 abundance of total PBMCs at baseline $(p_{\text{adi}}=0.0279)$ (figure 3A,B). No significant 366 differences were observed in the relative abundances of other cell subsets between the 367 groups at baseline. As the short-term survivors provided only baseline samples, we 368 could not compare other timepoints between the groups.

369

370 Oleclumab/durvalumab treatment was accompanied by significant CD14⁺CD16⁻ 371 **myeloid cell expansion**

372 To ensure consistency and sufficient sample size for adequate statistical power when 373 analyzing longitudinal changes, we evaluated only the samples from long-term survivors 374 taken at baseline ($n=7$) and after two ($n=7$) and four treatment cycles ($n=7$). Compared 375 ito baseline, the average frequency of classical monocytes (CD14⁺CD16⁻HLA-DR^{+/hi}) in 376 the peripheral blood samples significantly increased ($p_{\text{adi}}=0.0248$) after two treatment 377 cycles and remained elevated even after four treatment cycles, although not significantly 378 ($p_{\text{adi}}=0.299$) (figure 3C, left panel). Although there were no significant differences in the 379 relative abundances of monocytic myeloid-derived suppressor cells (M-MDSCs) 380 $\,(CD14^+CD16^+HLA-DR^{-/10})$ over time when analyzed separately from classical monocytes 381 (figure 3C, middle panel), removing the division between classical monocytes and M-382 MDSCs based on HLA-DR expression (online supplemental figure S2) revealed a

383 significant expansion of CD14⁺CD16 myeloid cells relative to baseline. This expansion 384 was evident after two treatment cycles $(p_{\text{adi}}=0.0165)$ and persisted even after four 385 treatment cycles ($p_{\text{adi}}=0.0231$) (figure 3C, right panel). We visualized this progressive 386 increase in abundance by using UMAP to generate density-colored projections of 387 aggregate samples of PBMCs from each timepoint (figure 3D).

388

389 **Myeloid MDSC expansion and central memory T-cell contraction are tied to** 390 **progression onset**

391 All seven patients in the long-term survivor group experienced tumor progression and 392 were subsequently categorized either as rapid progressors (n=3), who experienced 393 disease progression within the first 16 weeks (four cycles) of treatment, or slow 394 progressors (n=4), who had disease progression more than 16 weeks from the start of 395 treatment. Differential abundance analyses showed significant expansion of the M-396 MDSC subset after four treatment cycles in the rapid progressors ($p_{\text{adi}}=6.89\times10^{-8}$) (figure 397 3E, left panel), with no significant longitudinal changes in subset abundance occurring in 398 the slow progressors (figure 3E, right panel). Furthermore, among rapid progressors, we 399 observed a consistent decline, leading to a statistically significant contraction, of both 400 CD4⁺ ($p_{adj}=0.0477$) and CD8⁺ ($p_{adj}=0.0477$) central memory (CD27⁺CD45RO⁺CD45RA) 401 T-cell (T_{CM}) subsets after four treatment cycles (figure 3F, two left panels). This trend 402 was not observed among the slow progressors (figure 3F, two right panels).

403 For five out of the seven long-term survivors, samples from before and after confirmation 404 of progression were available. We noted a marked trend towards increased abundance

405 of M-MDSCs following progression (figure 3G); however, this did not reach statistical 406 significance $(p_{\text{adi}}=0.0537)$.

407

408 **PD-L1 expression is upregulated on T cells during oleclumab/durvalumab** 409 **treatment**

410 We subsequently performed differential analyses of cell state marker expression levels 411 to investigate inter-group differences and longitudinal changes in the activation, 412 exhaustion, or terminal differentiation of leukocytes, as well as in the activity of signaling 413 pathways potentially influenced by inhibition of adenosinergic signaling [30]. Differential 414 analyses of state marker expression levels between treatment timepoints and baseline 415 in the long-term survivors revealed significant upregulation of PD-L1 expression across 416 nearly all CD4⁺ and CD8⁺ T-cell subsets (figure 4). After two treatment cycles, PD-L1 417 expression was significantly increased in all memory (CD45RO⁺) T-cell subsets and 418 across all CD4+ T-cell subsets, with the CD4⁺ memory T cells showing the highest 419 expression and largest increases (figure 4A - left panel; figure 4B). Following four 420 treatment cycles, PD-L1 expression was significantly elevated compared to baseline in 421 all T-cell subsets except the effector memory (CD27 CD45RO⁺CD45RA) T-cell subsets 422 (figure 4A - right panel; figure 4B). Notably, the lowest PD-L1 expression among the T-423 cell subsets was observed in the naive (CD27⁺CD45RO⁻CD45RA⁺) T-cell subsets (figure 424 4B).

425 Comparisons of cell state marker expression between rapid and slow progressors, as 426 well as between pre- and post-progression samples, did not reveal any significant

427 differences. Interestingly, no significant changes or trends were observed in the 428 expression levels of markers associated with the adenosinergic signaling pathway 429 (CD39, CD73, p-CREB, and p-S6) (data not shown).

430

431 **Baseline expression levels of CD73 and IDO1 positively correlate with the duration** 432 **of progression-free survival**

433 To assess the impact of baseline abundances and phenotypes of peripheral blood 434 leukocytes on PFS duration, we performed correlation analyses. No significant valid 435 correlations were found between baseline subset abundances and PFS duration (figure 436 5A) (online supplemental table S3). However, analyses of cell state marker expression 437 revealed a strong positive correlation between baseline CD73 expression and PFS 438 duration for most of the subsets comprising the patients' peripheral blood leukocyte 439 repertoire (figure 5B). This correlation met the predefined robustness criteria in 440 approximately one third of leukocyte subsets, predominantly encompassing the majority 441 of the T-cell repertoire. Similarly, a strongly positive correlation with PFS duration was 442 also observed for baseline IDO1 expression in a number of leukocyte subsets, although 443 this correlation was significant in fewer subsets than observed for CD73 expression 444 (figure 5C).

445

446 **DISCUSSION**

447 In this study, we report the findings from a high-dimensional single-cell analysis of blood 448 samples from patients with relapsed EOC undergoing combination

449 oleclumab/durvalumab immunotherapy. To the best of our knowledge, this is the first 450 study to employ single-cell CyTOF to assess blood-based biomarkers in patients with 451 ovarian cancer undergoing immunotherapy. Through differential and correlative analyses 452 of the abundances and phenotypes of peripheral blood leukocytes, we identified 453 phenotypic signatures potentially indicative of disease progression and treatment 454 efficacy. We show that patients with relapsed EOC who present with lower proportions of 455 PBMCs in their peripheral blood leukocyte pool may derive inferior survival benefit from 456 combined oleclumab/durvalumab treatment than patients with higher proportions of 457 PBMCs. During treatment, we saw an increase in the relative abundance of circulating 458 CD14⁺CD16⁻ myeloid cells in the total patient cohort, along with a decrease in T_{CM} cell 459 proportions specific to rapidly progressing patients. We also observed a strong trend 460 towards an increased relative abundance of circulating M-MDSCs at progression. 461 Furthermore, we noted a significant increase in PD-L1 expression on circulating T cells 462 during treatment. Finally, we demonstrate that PFS duration was positively correlated 463 with pre-treatment expression levels of CD73 and IDO1 on several circulating leukocyte 464 subsets.

465 In our study cohort, long-term survivors exhibited significantly higher proportions of total 466 PBMCs at baseline compared to short-term survivors, which aligns with studies on PD-467 1/PD-L1 checkpoint blockade in lung cancer and melanoma demonstrating significant 468 association between lower baseline neutrophil-to-lymphocyte ratios and improved 469 progression-free and overall survival [31,32]. Correspondingly, patient P4, who exhibited 470 the highest relative abundance of lymphocytes at baseline among all patients (figure 471 2D), was the sole responder in the trial and demonstrated the longest survival. This data

472 suggests that EOC patients possessing an immune system more effectively primed for 473 adaptive response may derive more consistent benefit from immunotherapy.

474 We observed a significant expansion of the CD14⁺CD16⁻ myeloid cell compartment over 475 the course of the first four treatment cycles. This expansion was initially driven by an 476 increased abundance of HLA-DR^{+/hi} classical monocytes in the total cohort, and further 477 sustained by an elevated frequency of HLA-DR 4 ^o M-MDSCs in rapid progressors. This 478 indicates a shift of the CD14⁺CD16 myeloid compartment towards a more 479 immunosuppressive phenotype. Therefore, a sudden increase in the proportions of M-480 MDSCs in the peripheral blood of EOC patients treated with anti-CD73/PD-L1 481 immunotherapy may serve as a potential biomarker of disease progression. Accordingly, 482 higher HLA-DR expression on cells within the CD14⁺CD16⁻ myeloid cell compartment 483 has been positively associated with improved response to oleclumab [21] and 484 immunotherapy targeting the PD-1/PD-L1 pathway [33]. Furthermore, cancer 485 immunotherapy trials have consistently demonstrated that elevated MDSC abundance is 486 associated with worse outcome in EOC [34], and various other cancers [35-37]. Growth 487 factors and proinflammatory cytokines produced by cancer cells chronically stimulate 488 myeloid progenitors, driving their differentiation towards M-MDSCs. Similarly, tumor-489 derived factors can induce the reprogramming of classical monocytes already present in 490 peripheral blood towards M-MDSCs [38]. This expanded population of CD14⁺CD16⁻ 491 myeloid cells, likely representing precursors to tumor-associated macrophages, can be 492 recruited to ovarian tumors, resulting in enhanced immunosuppression [34]. We 493 hypothesize that EOC's concurrent utilization of a multitude of immunosuppressive 494 mechanisms allows it to adapt and effectively resist targeted immunotherapy through

495 enhancement of immunosuppression mechanisms not currently affected by treatment. 496 Such adaptation may be addressed by modifications or additions to the existing 497 therapeutic approach. In line with this notion, MDSC-targeting agents have been 498 preclinically and clinically evaluated in EOC with promising beneficial effect, also in 499 combination with other immunotherapeutic approaches [34,39].

500 Our analysis showed a significant decline in the frequencies of T_{CM} cells in the 501 peripheral blood of rapid progressors. Such a decline may have occurred as a 502 consequence of the evolving immunosuppression in the underlying cancer. This 503 hypothesis is supported by the observation that the T_{CM} -cell decline coincides with a 504 substantial increase in peripheral M-MDSCs in these patients. T_{CM} -cell homeostasis may 505 have been disrupted by the collective inhibition of the activation and differentiation of 506 effector T cells into T_{CM} cells, and the inhibition of the reactivation and proliferation of 507 tumor-proximal T_{CM} cells through an adaptive increase in adenosine generation. This 508 effect may have been mediated by upregulation or induction of CD39/CD73 expression 509 on tumor-recruited MDSCs [40], creating what is known as a "purinergic halo" [41]. The 510 role of adenosine in driving the contraction of the T_{CM} subset is further supported the 511 study of Mastelic-Gavillet et al., which showed that T_{CM} cells are especially vulnerable to 512 adenosine-mediated dysfunction due to their high expression of the A2A receptor [30].

513 A novel observation of this study was the significant increase of PD-L1 on circulating T 514 cells over time during administration of an anti-PD-L1 ICI. Research on other solid 515 cancers has identified intratumoral PD-L1⁺CD8⁺ T cells as drivers of T-cell exhaustion 516 via the PD-L1/PD-1 axis, and as promoters of M2 macrophage polarization [42,43]. 517 Given that PD-L1 upregulation on T cells occurs following activation, we postulate that

518 the observed longitudinal upregulation of PD-L1 on circulating T cells in patients with 519 EOC receiving oleclumab/durvalumab is a consequence of rapidly induced and 520 progressively mutual exhaustion of activated T-cells.

521 Interestingly, we did not observe any significant longitudinal changes or inter-group 522 differences in the expression of markers associated with adenosinergic signaling (CD39, 523 CD73, p-S6, and p-CREB). This contradicts previous findings that documented 524 oleclumab-induced inhibition and internalization of CD73 on $CD4^+$ and $CD8^+$ T cells [44]. 525 The stability of adenosinergic signaling observed in our study may be attributable to 526 compensatory upregulation of CD73 expression, which possibly counteracted the 527 expected oleclumab-mediated internalization.

528 Our study demonstrates a significant positive correlation between baseline CD73 529 expression across various leukocyte subsets and PFS duration. This contradicts the 530 prevailing view that CD73 expression in cancer generally correlates with poorer 531 treatment outcome [45]. A limited number of studies have investigated CD73 expression 532 in EOC [18,46], and ours is the first to link baseline CD73 expression with outcome in 533 CD73-targeting cancer therapy. Although the positive correlation between baseline 534 CD73 expression and PFS duration was observed for a range of leukocyte subsets, 535 nearly all T-cell subsets are present in this set and represent a majority of the significant 536 results. Thus, elevated baseline CD73 expression on peripheral blood T cells may serve 537 as a predictive marker of longer PFS in patients with EOC set to undergo anti-CD73 538 immunotherapy. We hypothesize that patients with higher baseline CD73 expression 539 may have had tumors more heavily dependent on adenosinergic signaling for immune 540 evasion, potentially enhancing the effectiveness of anti-CD73 treatment. Nonetheless,

541 this advantage appears to be temporary, as all patients ultimately experienced 542 progression. This development may be attributed to the inherent immunosuppressive 543 adaptability of EOC, as evident by the observed expansion of M-MDSCs and 544 upregulation of PD-L1 in T cells.

545 In addition to the observed positive correlation between CD73 and longer PFS, our 546 observation of a positive correlation between baseline IDO1 expression and longer PFS 547 during EOC immunotherapy is in alignment with previous reports [47,48]. Although IDO1 548 is generally viewed as a contributor to immunosuppression, our findings may be 549 explained by its role in upregulating PD-L1 through the activation of the aryl hydrocarbon 550 receptor by IDO1-generated tryptophan catabolites, as observed in solid tumors [49] and 551 murine models of EOC [50]. Consequently, higher IDO1 expression in specific cell 552 subsets could lead to increased PD-L1 expression on the same cells, potentially 553 enhancing their susceptibility to durvalumab. Indeed, consistent with the study by 554 Fujiwara et al. [47], our data also demonstrated a positive correlation between IDO1 and 555 PD-L1 expression in leukocytes (online supplemental table S4). This correlation was 556 significant and robust in subsets that showed the strongest associations between PD-L1 557 expression and PFS duration, namely, classical monocytes, M-MDSCs, and CD141⁺ 558 myeloid dendritic cells. Therefore, IDO1 expression in the peripheral blood myeloid 559 compartment may serve as a potential biomarker for the efficacy of EOC immunotherapy 560 targeting PD-L1. Despite strong correlation coefficients and significant p-values, the 561 validity of correlations between PD-L1 and PFS duration was limited by a low goodness-562 of-fit parameter, likely due to the small sample size. Therefore, a larger study is needed

563 to more definitively establish baseline PD-L1 expression in peripheral blood leukocytes 564 as a predictive biomarker for EOC immunotherapy utilizing anti-PD-L1 ICIs.

565 This study examined sequentially sampled peripheral blood. An advantage of using 566 blood samples, as opposed to tumor tissue biopsies, is that the information provided is 567 not limited to a specific anatomical location. This is particularly valuable in cases of 568 metastatic disease and offers a more comprehensive view of the patient's overall 569 condition. Additionally, blood sampling is more flexible, clinically accessible, cost-570 effective, less invasive, and avoids the need for radiological imaging or surgical 571 procedures for sample acquisition. However, the implementation of our 40-marker panel 572 in the clinical setting is constrained by the high costs and complexity of the CyTOF 573 methodology. Therefore, a more focused set of markers or leukocyte subsets, as 574 suggested in this study, could represent a biomarker panel analyzable via methods 575 already utilized in routine clinical diagnostics, such as flow cytometry or ELISA.

576 Overall, the small number of patient samples in this study affects the statistical power 577 and limits the generalizability of the results. However, the diversity within the patient 578 population - encompassing a wide range of ages, disease stages, and prior treatments - 579 adds to the robustness and relevance of our observations for a broader spectrum of 580 patients with relapsed EOC undergoing immunotherapy. Furthermore, the use of single-581 cell suspension CyTOF allowed us to generate extensive data from the limited sample 582 set. Coupled with high-dimensional unsupervised clustering algorithms, this approach 583 provided numerous insights and perspectives, strengthening the conclusions of the 584 study.

585 Another limitation of this study is the absence of control arms comprising patients 586 treated with either oleclumab or durvalumab alone [15]. Such control groups would have 587 provided data integral for the conclusive attribution of the observed differences in 588 leukocyte abundances and states to the effects of a certain immunotherapeutic. In 589 addition, patients had undergone multiple rounds of cancer therapy prior to inclusion, 590 which may have exerted developmental pressure on the tumors and potentially 591 influenced response to oleclumab/durvalumab treatment. Although an expanded trial 592 including single-agent arms and newly diagnosed EOC patients would help clarify the 593 individual contribution of each compound to treatment outcome, the limited clinical 594 activity of the oleclumab/durvalumab combination in the NSGO-OV-UMB1 trial [15] 595 makes it difficult and ethically questionable to initiate such a randomized phase II or III 596 trial.

597 In conclusion, our findings offer comprehensive insights into the effects of combination 598 oleclumab/durvalumab immunotherapy on the peripheral blood leukocytes of relapsed 599 EOC patients and elucidate potential immunosuppressive mechanisms employed by 600 EOC to counteract the effects of immunotherapy. We propose blood-based biomarkers 601 for better patient selection and non-invasive monitoring of disease progression; however, 602 validation in larger patient cohorts is necessary.

603

604 **DECLARATIONS**

605 **Author affiliations**

- 606 ¹ Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of
- 607 Bergen, Bergen, Norway
- 608 ² Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen,
- 609 Norway
- 610 ³ Department of Obstetrics and Gynecology and Tays Cancer Centre, Tampere University
- 611 Hospital, Tampere, Finland
- 612 ⁴ Nordic Society of Gynaecological Oncology Clinical Trial Unit (NSGO-CTU), Tampere,
- 613 Finland
- 614 5 Nordic Society of Gynaecological Oncology Clinical Trial Unit (NSGO-CTU),
- 615 Copenhagen, Denmark
- 616 ⁶Department of Health Registry Research and Development, Norwegian Institute of
- 617 Public Health, Oslo, Norway
- 618 *Kinn* Therapeutics AS, Bergen, Norway
- 619 ⁸ Centre for Pharmacy, Department of Clinical Science, University of Bergen, Bergen,
- 620 Norway
- 621 ⁹ Department of Internal Medicine, Hematology Section, Haukeland University Hospital,
- 622 Bergen, Norway
- 623 ¹⁰ Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
- 624 ¹¹ Department of Oncology, Rigshospitalet, Copenhagen University Hospital, 625 Copenhagen, Denmark

626

627 **Acknowledgements** We thank the patients for their consent and participation in 628 the study. We thank Brith Bergum and Jørn Skavland at the Flow Cytometry Core 629 Facility of the University of Bergen for providing support for our mass cytometry work. 630 We acknowledge BioRender.com as the platform used to create the figures in this 631 manuscript.

632

633 **Authors' Contributions** Study conceptualization and design: LT, MRM, LB. Clinical 634 sample collection: AA, JM, KM, KSP, MRM, LB. Clinical database administration: RdPC, 635 KM, KSP. Data generation: LT, CEW. Data analysis and statistics: LT. Data interpretation: 636 LT, KK, LCVT, EMC, LB. Manuscript writing and editing: LT, KK, LCVT, LB. Manuscript 637 review: All authors. Project administration: LT, KM, KSP, MRM, LB. Funding acquisition: 638 MRM, LB. Guarantors: MRM, LB.

639

640 **Funding** This work was supported by grants from the Western Norway Regional 641 Health Authority (Project No. 28543) and the Research Council of Norway through its 642 Centres of Excellence funding scheme (Project No. 223250). AstraZeneca provided a 643 grant to partially fund the trial and the investigational medicinal products (oleclumab and 644 durvalumab). The funding sources were not involved in the study design, the collection 645 of data, or the analysis and interpretation of data.

646

647 **Competing interests** AA has participated on the advisory boards of 648 GlaxoSmithKline and Merck Sharp and Dohme; RdPC is employed by and is a 649 shareholder of Y-mAbs Pharmaceuticals; LCVT has received personal fees for lectures 650 from Bayer and AstraZeneca, personal fee payments from Eisai for participating on an

651 expert board, and has received a grant related to a clinical trial from AstraZeneca; CEW 652 has received financial support for conference attendance and travel expenses from 653 Beckman Coulter Inc.; EMC is a shareholder of KinN Therapeutics AS; JM has received 654 a honorarium for a lecture from Eisai; KM has received speakers' honoraria and 655 received compensation for travel expenses from GlaxoSmithKline and AstraZeneca, has 656 participated in a trial-specific safety review committee for Kancera AB, and is a deputy 657 medical director for NSGO-CTU; MRM has received an institutional study grant and 658 investigational medicinal product from AstraZeneca (no personal grants were received); 659 LB has received honoraria for lectures from GlaxoSmithKline and Merck Sharp and 660 Dohme, has received a research grant from AstraZeneca for a researcher-initiated trial, 661 and has had leadership roles in Onkologisk Forum between 2018 and 2022 and in the 662 NSGO and NSGO-CTU since 2021; LT, KK and KSP report no personal conflicts of 663 interest.

664

665 **Data availability statement** Data are available from the corresponding author 666 upon request.

667

668 **Ethics approval** The study protocol and use of patient material in this study was 669 approved by the regional ethical committees or institutional review boards of the 670 participating sites: The Scientific Ethics Committee for the Capital Region of Denmark 671 (VEK) (approval no. H-17025483), The Regional Committee for Medical Research 672 Ethics Western Norway (REK West) (approval no. 2018/580), and The Regional Ethics

673 Committee of the Expert Responsibility area of Tampere University Hospital (TAYS) 674 (approval no. R18078M). The study was conducted in accordance with the good clinical 675 practice guidelines and provisions of the Declaration of Helsinki, as well as according to 676 all local regulations.

677

678 **Patient consent** All patients provided written informed consent for use of the clinical 679 information and biological materials.

680

681 **Provenance and peer review** Not commissioned; externally peer reviewed.

682

683 **Supplemental material** This content has been supplied by the author(s). It has not 684 been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-685 reviewed. Any opinions or recommendations discussed are solely those of the author(s) 686 and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from 687 any reliance placed on the content. Where the content includes any translated material, 688 BMJ does not warrant the accuracy and reliability of the translations (including but not 689 limited to local regulations, clinical guidelines, terminology, drug names and drug 690 dosages), and is not responsible for any error and/or omissions arising from translation 691 and adaptation or otherwise.

692

693 **Open access** This is an open access article distributed in accordance with the 694 Creative Commons Attribution (CC BY 4.0) license, which permits others to copy, 695 redistribute, remix, transform and build upon this work for any purpose, provided the 696 original work is properly cited, appropriate credit is given, any changes made are 697 indicated. See: https://creativecommons.org/licenses/by/4.0/.

- 698
- 699 **ORCID IDs**
- 700 Luka Tandaric https://orcid.org/0009-0009-1431-2586
- 701 Annika Auranen https://orcid.org/0000-0002-9678-4684
- 702 Katrin Kleinmanns https://orcid.org/0000-0003-1402-8568
- 703 René DePont Christensen https://orcid.org/0009-0007-0919-236X
- 704 Liv Cecilie Vestrheim Thomsen https://orcid.org/0000-0002-6787-8518
- 705 Cara Ellen Wogsland https://orcid.org/0000-0003-1797-7902
- 706 Emmet McCormack https://orcid.org/0000-0002-7621-4625
- 707 Johanna Mäenpää https://orcid.org/0000-0003-0486-6912
- 708 Kristine Madsen https://orcid.org/0009-0004-4552-1931
- 709 Karen Stampe Petersson https://orcid.org/0009-0008-9757-1913
- 710 Mansoor Raza Mirza https://orcid.org/0000-0002-8085-1010
- 711 Line Bjørge https://orcid.org/0000-0002-0240-2770

712

713 **REFERENCES**

714 [1] L. Kuroki, S.R. Guntupalli. Treatment of epithelial ovarian cancer. BMJ 371 (2020) 715 m3773. DOI:10.1136/bmj.m3773

716 [2] A. Gadducci, S. Cosio. Randomized Clinical Trials and Real World Prospective 717 Observational Studies on Bevacizumab, PARP Inhibitors, and Immune Checkpoint 718 Inhibitors in the First-Line Treatment of Advanced Ovarian Carcinoma: A Critical Review. 719 Anticancer Res 41(10) (2021) 4673-4685. DOI:10.21873/anticanres.15281

720 [3] S.L. Cooke, J.D. Brenton. Evolution of platinum resistance in high-grade serous 721 ovarian cancer. Lancet Oncol 12(12) (2011) 1169-1174. DOI:10.1016/S1470- 722 2045(11)70123-1

723 [4] M. McMullen, A. Madariaga, S. Lheureux. New approaches for targeting platinum-724 resistant ovarian cancer. Semin Cancer Biol 77 (2021) 167-181. 725 DOI:10.1016/j.semcancer.2020.08.013

726 [5] H.E. Marei, A. Hasan, G. Pozzoli, et al., Cancer immunotherapy with immune 727 checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for 728 reinvigorating T cell responsiveness when resistance is acquired. Cancer Cell Int 23(1) 729 (2023) 64. DOI:10.1186/s12935-023-02902-0

730 [6] L. Zhang, J.R. Conejo-Garcia, D. Katsaros, et al., Intratumoral T cells, recurrence, 731 and survival in epithelial ovarian cancer. N Engl J Med 348(3) (2003) 203-213. 732 DOI:10.1056/NEJMoa020177

733 [7] T.J. Curiel, G. Coukos, L. Zou, et al., Specific recruitment of regulatory T cells in 734 ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 735 10(9) (2004) 942-949. DOI:10.1038/nm1093

736 [8] A. Varga, S. Piha-Paul, P.A. Ott, et al., Pembrolizumab in patients with 737 programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-738 028. Gynecol Oncol 152(2) (2019) 243-250. DOI:10.1016/j.ygyno.2018.11.017

739 [9] B.A. Maiorano, M.F.P. Maiorano, D. Lorusso, et al., Ovarian Cancer in the Era of 740 Immune Checkpoint Inhibitors: State of the Art and Future Perspectives. Cancers 741 (Basel) 13(17) (2021). DOI:10.3390/cancers13174438

742 [10] C. Yang, B.R. Xia, Z.C. Zhang, et al., Immunotherapy for Ovarian Cancer: 743 Adjuvant, Combination, and Neoadjuvant. Front Immunol 11 (2020) 577869. 744 DOI:10.3389/fimmu.2020.577869

745 [11] A. Martinez, J.P. Delord, M. Ayyoub, et al., Preclinical and Clinical 746 Immunotherapeutic Strategies in Epithelial Ovarian Cancer. Cancers (Basel) 12(7) 747 (2020). DOI:10.3390/cancers12071761

748 [12] B. Allard, S. Pommey, M.J. Smyth, et al., Targeting CD73 enhances the antitumor 749 activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res 19(20) (2013) 5626-5635. 750 DOI:10.1158/1078-0432.CCR-13-0545

751 [13] F. Polesso, A.D. Weinberg, A.E. Moran. Late-Stage Tumor Regression after PD-752 L1 Blockade Plus a Concurrent OX40 Agonist. Cancer Immunol Res 7(2) (2019) 269- 753 281. DOI:10.1158/2326-6066.CIR-18-0222

754 [14] W.L. Redmond, S.N. Linch, M.J. Kasiewicz. Combined targeting of costimulatory 755 (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of 756 driving robust antitumor immunity. Cancer Immunol Res 2(2) (2014) 142-153. 757 DOI:10.1158/2326-6066.CIR-13-0031-T

758 [15] M.R. Mirza, L. Tandaric, J.R. Henriksen, et al., NSGO-OV-UMB1/ENGOT-OV30: 759 A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody 760 Oleclumab in patients with relapsed ovarian cancer. Gynecol Oncol 188 (2024) 103-110. 761 DOI:10.1016/j.ygyno.2024.06.017

762 [16] M. Uhlen, L. Fagerberg, B.M. Hallstrom, et al., Proteomics. Tissue-based map of 763 the human proteome. Science 347(6220) (2015) 1260419. 764 DOI:10.1126/science.1260419

765 [17] M. Uhlen, C. Zhang, S. Lee, et al., A pathology atlas of the human cancer 766 transcriptome. Science 357(6352) (2017). DOI:10.1126/science.aan2507

767 [18] M. Turcotte, K. Spring, S. Pommey, et al., CD73 is associated with poor prognosis 768 in high-grade serous ovarian cancer. Cancer Res 75(21) (2015) 4494-4503. 769 DOI:10.1158/0008-5472.CAN-14-3569

770 [19] F. Ghiringhelli, M. Bruchard, F. Chalmin, et al., Production of adenosine by 771 ectonucleotidases: a key factor in tumor immunoescape. J Biomed Biotechnol 2012 772 (2012) 473712. DOI:10.1155/2012/473712

773 [20] S. Chen, D.A. Wainwright, J.D. Wu, et al., CD73: an emerging checkpoint for 774 cancer immunotherapy. Immunotherapy 11(11) (2019) 983-997. DOI:10.2217/imt-2018- 775 0200

776 [21] C.M. Hay, E. Sult, Q. Huang, et al., Targeting CD73 in the tumor 777 microenvironment with MEDI9447. Oncoimmunology 5(8) (2016) e1208875. 778 DOI:10.1080/2162402X.2016.1208875

779 [22] M. Moller, V. Orth, V. Umansky, et al., Myeloid-derived suppressor cells in 780 peripheral blood as predictive biomarkers in patients with solid tumors undergoing

781 immune checkpoint therapy: systematic review and meta-analysis. Front Immunol 15 782 (2024) 1403771. DOI:10.3389/fimmu.2024.1403771

783 [23] K. Okla, A. Czerwonka, A. Wawruszak, et al., Clinical Relevance and 784 Immunosuppressive Pattern of Circulating and Infiltrating Subsets of Myeloid-Derived 785 Suppressor Cells (MDSCs) in Epithelial Ovarian Cancer. Front Immunol 10 (2019) 691. 786 DOI:10.3389/fimmu.2019.00691

- 787 [24] E.R. Zunder, R. Finck, G.K. Behbehani, et al., Palladium-based mass tag cell 788 barcoding with a doublet-filtering scheme and single-cell deconvolution algorithm. Nat 789 Protoc 10(2) (2015) 316-333. DOI:10.1038/nprot.2015.020
- 790 [25] S. Granjeaud. cytoBatchNorm. 2022; https://github.com/i-cyto/cytoBatchNorm. 791 (Accessed: 01. Sep. 2024)
- 792 [26] S. Van Gassen, B. Callebaut, M.J. Van Helden, et al., FlowSOM: Using self-793 organizing maps for visualization and interpretation of cytometry data. Cytometry A 87(7) 794 (2015) 636-645. DOI:10.1002/cyto.a.22625
- 795 [27] E. Becht, L. McInnes, J. Healy, et al., Dimensionality reduction for visualizing 796 single-cell data using UMAP. Nat Biotechnol (2018). DOI:10.1038/nbt.4314
- 797 [28] H. Crowell, V. Zanotelli, S. Chevrier, et al. CATALYST: Cytometry dATa anALYSis 798 Tools. R package version 1.28.0. 2024; https://github.com/HelenaLC/CATALYST. 799 (Accessed: 01. Sep. 2024)
- 800 [29] L.M. Weber, M. Nowicka, C. Soneson, et al., diffcyt: Differential discovery in high-801 dimensional cytometry via high-resolution clustering. Commun Biol 2 (2019) 183. 802 DOI:10.1038/s42003-019-0415-5
- 803 [30] B. Mastelic-Gavillet, B. Navarro Rodrigo, L. Decombaz, et al., Adenosine 804 mediates functional and metabolic suppression of peripheral and tumor-infiltrating 805 CD8(+) T cells. J Immunother Cancer 7(1) (2019) 257. DOI:10.1186/s40425-019-0719-5
- 806 [31] Y. Li, Z. Zhang, Y. Hu, et al., Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) 807 May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients 808 Treated With Immune Checkpoint Inhibitors (ICIs). Front Oncol 10 (2020) 654. 809 DOI:10.3389/fonc.2020.00654
- 810 [32] J.T. Cohen, T.J. Miner, M.P. Vezeridis. Is the neutrophil-to-lymphocyte ratio a 811 useful prognostic indicator in melanoma patients? Melanoma Manag 7(3) (2020) 812 MMT47. DOI:10.2217/mmt-2020-0006
- 813 [33] C. Krieg, M. Nowicka, S. Guglietta, et al., High-dimensional single-cell analysis 814 predicts response to anti-PD-1 immunotherapy. Nat Med 24(2) (2018) 144-153. 815 DOI:10.1038/nm.4466

816 [34] K. Okla. Myeloid-Derived Suppressor Cells (MDSCs) in Ovarian Cancer-Looking 817 Back and Forward. Cells 12(14) (2023). DOI:10.3390/cells12141912

818 [35] P. Kongsted, T.H. Borch, E. Ellebaek, et al., Dendritic cell vaccination in 819 combination with docetaxel for patients with metastatic castration-resistant prostate 820 cancer: A randomized phase II study. Cytotherapy 19(4) (2017) 500-513. 821 DOI:10.1016/j.jcyt.2017.01.007

822 [36] C. Meyer, L. Cagnon, C.M. Costa-Nunes, et al., Frequencies of circulating MDSC 823 correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer 824 Immunol Immunother 63(3) (2014) 247-257. DOI:10.1007/s00262-013-1508-5

825 [37] G. Enblad, H. Karlsson, G. Gammelgard, et al., A Phase I/IIa Trial Using CD19- 826 Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia. Clin Cancer Res 827 24(24) (2018) 6185-6194. DOI:10.1158/1078-0432.CCR-18-0426

828 [38] K. Li, H. Shi, B. Zhang, et al., Myeloid-derived suppressor cells as 829 immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct 830 Target Ther 6(1) (2021) 362. DOI:10.1038/s41392-021-00670-9

831 [39] Y. Berckmans, Y. Hoffert, A. Vankerckhoven, et al., Drug Repurposing for 832 Targeting Myeloid-Derived Suppressor-Cell-Generated Immunosuppression in Ovarian 833 Cancer: A Literature Review of Potential Candidates. Pharmaceutics 15(7) (2023). 834 DOI:10.3390/pharmaceutics15071792

835 [40] J. Li, L. Wang, X. Chen, et al., CD39/CD73 upregulation on myeloid-derived 836 suppressor cells via TGF-beta-mTOR-HIF-1 signaling in patients with non-small cell lung 837 cancer. Oncoimmunology 6(6) (2017) e1320011. DOI:10.1080/2162402X.2017.1320011

838 [41] L. Antonioli, P. Pacher, E.S. Vizi, et al., CD39 and CD73 in immunity and 839 inflammation. Trends Mol Med 19(6) (2013) 355-367. 840 DOI:10.1016/j.molmed.2013.03.005

841 [42] B. Diskin, S. Adam, M.F. Cassini, et al., PD-L1 engagement on T cells promotes 842 self-tolerance and suppression of neighboring macrophages and effector T cells in 843 cancer. Nat Immunol 21(4) (2020) 442-454. DOI:10.1038/s41590-020-0620-x

844 [43] Y. Zheng, L. Han, Z. Chen, et al., PD-L1(+)CD8(+) T cells enrichment in lung 845 cancer exerted regulatory function and tumor-promoting tolerance. iScience 25(2) (2022) 846 103785. DOI:10.1016/j.isci.2022.103785

847 [44] J. Bendell, P. LoRusso, M. Overman, et al., First-in-human study of oleclumab, a 848 potent, selective anti-CD73 monoclonal antibody, alone or in combination with 849 durvalumab in patients with advanced solid tumors. Cancer Immunol Immunother 72(7) 850 (2023) 2443-2458. DOI:10.1007/s00262-023-03430-6

851 [45] N. Bach, R. Winzer, E. Tolosa, et al., The Clinical Significance of CD73 in Cancer. 852 Int J Mol Sci 24(14) (2023). DOI:10.3390/ijms241411759

853 [46] H.K. Oh, J.I. Sin, J. Choi, et al., Overexpression of CD73 in epithelial ovarian 854 carcinoma is associated with better prognosis, lower stage, better differentiation and 855 lower regulatory T cell infiltration. J Gynecol Oncol 23(4) (2012) 274-281. 856 DOI:10.3802/jgo.2012.23.4.274

857 [47] Y. Fujiwara, S. Kato, D. Nishizaki, et al., High indoleamine 2,3-dioxygenase 858 transcript levels predict better outcome after front-line cancer immunotherapy. iScience 859 27(4) (2024) 109632. DOI:10.1016/j.isci.2024.109632

860 [48] I. Hoffmann, M.P. Dragomir, N. Monje, et al., Increased expression of IDO1 is 861 associated with improved survival and increased number of TILs in patients with high-862 grade serous ovarian cancer. Neoplasia 44 (2023) 100934. 863 DOI:10.1016/j.neo.2023.100934

864 [49] J.E. Kenison, Z. Wang, K. Yang, et al., The aryl hydrocarbon receptor suppresses 865 immunity to oral squamous cell carcinoma through immune checkpoint regulation. Proc 866 Natl Acad Sci U S A 118(19) (2021). DOI:10.1073/pnas.2012692118

867 [50] A. Amobi-McCloud, R. Muthuswamy, S. Battaglia, et al., IDO1 Expression in 868 Ovarian Cancer Induces PD-1 in T Cells via Aryl Hydrocarbon Receptor Activation. Front 869 Immunol 12 (2021) 678999. DOI:10.3389/fimmu.2021.678999

870

871 **FIGURE AND TABLE CAPTIONS**

872 **Figure 1** Trial overview, sample collection and processing. (A) Schema of the 873 patient disposition and immunotherapy administration schedule of the NSGO-OV-874 UMB1/ENGOT-OV30 trial. One treatment cycle had a duration of four weeks. (B) Blood 875 sample acquisition and processing workflow (full protocol provided in the online 876 supplemental appendix). (C) Swimmer plot illustrating the duration of treatment and 877 observation for each patient included in this study, as well as blood sampling timepoints. 878 IV – intravenous

880 **Online supplemental table S1** The 40-marker mass cytometry panel used for 881 immunophenotyping in this study. *Titrated on both non-stimulated leukocytes and 882 Stimulated PBMCs; [†]Titrated on stimulated PBMCs; [‡]Intracellular target; [§]Conjugated in-883 house

884

885 **Online supplemental figure S1** Cleanup gating workflow used for the refinement of 886 the raw cytometry by time-of-flight (CyTOF) data into intact single cells (singlets).

887

888 **Figure 2** Formation and overall view of the study dataset. (A) Heatmap of the 889 normalized median expression of the 13 markers (rows) used for the clustering of total 890 leukocytes. Each column represents a cluster. Appropriateness of leukocyte subset 891 assignment* was confirmed by unsupervised hierarchical clustering (visualized above 892 heatmap). (B) Heatmap of the normalized median expression of the 22 markers (rows) 893 used for the clustering of PBMCs. Each column represents a leukocyte subset. Subset 894 assignment* was performed and validated in the same manner as for the total leukocyte 895 clusters. (C) UMAP projection of an aggregated sample of PBMCs, consisting of an 896 equal number of cells sampled from each blood sample. Each cell is colored by subset 897 assignment*. (D) Overview of the leukocyte (upper stacked bar plots) and PBMC (lower 898 stacked bar plots) composition of all blood samples (detailed composition of each 899 sample is given in online supplemental table S2). *Leukocyte subset assignment 900 coloring is consistent throughout figure 2. TCRgd - gamma-delta T-cell receptor

901

902 **Table 1** Characteristics of the included patients.

903

904 **Figure 3** Significant differences, changes, and trends in the relative abundances of 905 leukocyte populations. (A) Comparison of the relative baseline abundances of 906 granulocytes and total PBMCs between survival duration groups (short-term survival is 907 defined as observed survival of at most 16 weeks since the start of treatment; long-term 908 survival is defined as observed survival of more than 16 weeks since the start of 909 treatment). Symbols representing each patient are consistent throughout all figures. (B) 910 UMAP projections of aggregated baseline samples of total leukocytes stratified by 911 survival duration group. Both projections consist of the same number of cells. The 912 significant difference in the density of the total PBMC subset between groups is 913 accented with a dashed blue outline. (C) Changes in the relative abundances of 914 classical monocytes and monocytic myeloid-derived suppressor cells (M-MDSCs) during 915 treatment in the group of long-term survivors (n=7). The two PBMC subsets composed 916 of CD14⁺CD16⁻ myeloid cells (Monocytes - Classical and M-MDSCs), are shown 917 separately in the left and middle panel. The level of HLA-DR expression forms the basis 918 for the separation of classical monocytes (HLA-DR^{+/hi}) from M-MDSCs (HLA-DR^{-/lo}) 919 (online supplemental figure S2). In the right panel, the classical monocyte and M-MDSC 920 subsets were merged to illustrate the significant and continued increase of the 921 abundance of CD14⁺CD16⁻ myeloid cells during treatment. (D) UMAP projections of 922 aggregated PBMC samples from the long-term survivors $(n=7)$, stratified by treatment

923 timepoint. Cells of the "Monocytes-Classical" and "M-MDSCs" subsets are delineated 924 with a blue outline. (E) Changes in the relative abundances of M-MDSCs during 925 treatment. Patients were stratified into rapid progressors (progression confirmed after at 926 most 16 weeks since the start of treatment) and slow progressors (progression 927 confirmed after more than 16 weeks since the start of treatment). (F) Changes in the 928 relative abundances of central memory (CM) T-cell subsets during treatment. Patients 929 were stratified into rapid- and slow progressors. (G) Comparison of the relative 930 abundances of M-MDSCs in samples collected at blood sampling timepoints 931 immediately before and after confirmation of disease progression. ns - not significant; * - 932 $p_{\text{adi}} < 0.05$; *** - $p_{\text{adi}} < 0.001$

933

934 **Online supplemental figure S2** Determination of the cutoff of HLA-DR expression for 935 the separation of classical monocytes and myeloid monocyte-derived suppressor cells. 936 (A) The subset of naïve $CD4^+$ T cells was used as a negative control for HLA-DR 937 expression. (B) The subset of naïve B cells was used as a positive control for HLA-DR 938 expression. (C) The cutoff of HLA-DR expression for the separation of the cells of the 939 CD14⁺CD16⁻ myeloid cell subset was set according to the optimal expression cutoffs in 940 the negative and positive control subsets.

941

942 **Online supplemental table S2** Detailed sample composition data.

944 **Figure 4** Significant changes in cell state marker expression during treatment. (A) 945 Heatmaps of the top significant differences in the relative state marker expression in 946 long-term survivor samples taken at baseline (n=7) (left half of the heatmaps) and after 947 either two (right half of left heatmap) or four treatment cycles (right half of right 948 heatmap). Each row of the heatmap is labeled with the combination of marker (left) and 949 subset (right, in brackets) it represents, sorted from top to bottom based on increasing p-950 value. (B) Median arcSinh(5)-transformed expression of PD-L1 over time for all T-cell 951 subsets in the long-term survivor (n=7) samples. The trendline was calculated using 952 simple linear regression. $*$ - p_{adi} < 0.05; CM - central memory; E - effector; EM - effector 953 memory; GranB - granzyme B; $logFC - log₂(fold change)$; Mono - monocytes; N - naïve; 954 NC - non-classical; NK-56 - CD56⁺⁺⁺ NK cells; NKT - NKT cells; ns - not significant; T-955 CD4 - CD4⁺ T cells; T-CD8 - CD8⁺ T cells; T-DN - CD4 CD8 (double-negative) T cells; 956 Tgd - gamma-delta T cells

957

958 **Figure 5** Correlations between progression-free survival duration and either the 959 relative leukocyte subset abundances or state marker expression levels at baseline for 960 long-term survivors (n=7). (A) Heatmap showing correlation analysis results (online 961 supplemental table S3). Pearson or Spearman correlation analysis was selected based 962 on the normality of the dataset, assessed using the Shapiro-Wilk test. (B) Plots depicting 963 significant correlations between transformed median CD73 expression at baseline and 964 time to progression. Symbols representing each patient are consistent throughout Fig. 5. 965 (C) Plots illustrating most significant correlations between transformed median IDO1 966 expression at baseline and time to progression. |r| - absolute value of Pearson's

- 967 correlation coefficient; |ρ| absolute value of Spearman's correlation coefficient; GranB -
- 968 granzyme B
- 969
- 970 **Online supplemental table S3** Full correlation testing results.

- 972 **Online supplemental table S4** Results of correlation testing between IDO1 and PD-
- 973 L1 expression at baseline.

B

笛

ă

D

